You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
TAT-Gap19(I130A) is a control peptide for TAT-Gap19 (Cat. No. 6227), a Cx43 hemichannel blocker. TAT-Gap19(I130A) consists of TAT-GAP19 with a I130A amino acid residue change at a key residue for GAP19 activity. In C6 glioma cells expression Cx43, TAT-GAP19(1130A) does not inhibit [Ca2+]i-triggered ATP release at 200 μM. TAT-Gap19(I130A) is cell permeable.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solubility||Soluble to 2 mg/ml in water|
References are publications that support the biological activity of the product.
Wang et al (2013) Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. Basic Res.Cardiol. 108 309 PMID: 23184389
Walrave et al (2016) Inhibition of connexin43 hemichannels impairs spatial short-term memory without affecting spatial working memory. Front.Cell Neurosci. 10 288 PMID: 28066184
If you know of a relevant reference for TAT-Gap19(I130A), please let us know.
View Related Products by Product Action
Keywords: TAT-Gap19(I130A), TAT-Gap19(I130A) supplier, TAT-gap19, control, peptide, Cx43, connexin, hemichannel, Gap, Channels, 7402, Tocris Bioscience
Citations for TAT-Gap19(I130A)
Citations are publications that use Tocris products.
Currently there are no citations for TAT-Gap19(I130A). Do you know of a great paper that uses TAT-Gap19(I130A) from Tocris? Please let us know.
Reviews for TAT-Gap19(I130A)
There are currently no reviews for this product. Be the first to review TAT-Gap19(I130A) and earn rewards!
Have you used TAT-Gap19(I130A)?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.